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Report on Wage Structure. We also use other information such
as the Korean Statistical Information System. RESULTS: The
estimated costs of cancer are as follows: 9.60 billion US PPP$ ($
hereafter) in 1999, $9.60 billion in 2000, $9.62 billion in 2001,
$9.01 billion in 2002, and $9.87 billion in 2003. We ﬁnd that
indirect cost accounts for about 80% of total cost during that
period, but the proportion has been dropped since 2000; from
84.6% in 2000 to 78.7% in 2003. The proportions of the 
cost of male and female cancer patients are about 77% and 23%
respectively during the period. The cost of three major cancers
in 2003 accounts for 53.3% of total cost of cancers: the cost of
liver cancer is $2.26 billion (22.9% of total cost of all cancers);
$1.67 billion (16.9%) in stomach cancer; and $1.33 billion
(13.5%) in bronchial and lung cancer. CONCLUSIONS: The
cost of cancer has been steadily increasing from 1999~2003
except 2002, while the proportion of indirect costs has gradu-
ally decreased since 2000.
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OBJECTIVES: Poorly controlled CINV may lead to additional
ofﬁce or emergency room visits, thus, increasing the overall costs
of cancer care. This study estimates the societal costs of uncon-
trolled CINV for working-age cancer patients. METHODS:
Employees or spouse and/or dependents with cancer who
received highly or moderately emetogenic chemotherapy were
identiﬁed from a 1997–2002 proprietary dataset linking medical
claims to work-loss information. Patients were followed from the
earliest date of chemotherapy for up to six-months, excluding
those with less than three-months of continuous enrollment.
Direct medical costs were measured using payments, normalized
as monthly, and updated to 2004 USD. Work loss days were
identiﬁed from employment records. Costs of uncontrolled
CINV were derived by comparing medical costs and work-loss
days for three groups, patients with uncontrolled CINV and 
no ER visit, with uncontrolled CINV and ER visit, and with 
controlled CINV, using the Wilcoxon Mann-Whitney test in 
univariate analyses. All patients with uncontrolled CINV were
pooled as one group in multivariate analysis. RESULTS: In all,
2,071 patients were identiﬁed; 25% required medical care for
uncontrolled CINV; 2% had ER visits. Compared with patients
with controlled CINV ($8132), total direct costs were signiﬁ-
cantly higher for patients with uncontrolled CINV, no ER
($10,376, P < 0.001) and uncontrolled CINV and ER ($12,810,
P < 0.001), respectively. Estimated work-loss days were 6.1, 7.2,
and 8.9 days the above groups, respectively. After controlling 
for demographics, geographic regions, and comorbidities, the
difference in monthly medical costs between the controlled 
and uncontrolled group was $2619 (P < 0.001). However, the
difference in work-loss (0.21 days) was no longer signiﬁcant 
(P = 0.73). CONCLUSIONS: Uncontrolled CINV was associated
with a signiﬁcant increase in medical costs. For patients with
uncontrolled CINV but no ER visit, increases in cost were driven
by outpatient care, whereas for those with ER visits, inpatient
care was the major cost driver.
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OBJECTIVES: A variety of pharmacologic therapies are avail-
able or in development for the prevention of breast cancer recur-
rence. Assessing the beneﬁts of these treatments is compromised
by a paucity of data on the impact of recurrence on economic
costs and patient survival. The purpose of this study was to shed
light on these issues. METHODS: We conducted a retrospective
analysis of SEER-Medicare data, which consists of information
from the SEER cancer registry linked to administrative claims
from the Medicare program. All patients in SEER who were
diagnosed with and treated for primary breast cancer during
1991–1993 were identiﬁed, and their subsequent Medicare
claims histories were scanned for evidence of recurrence. Patients
were stratiﬁed according to type of recurrence (local, contralat-
eral, or distant) and their Medicare claims further scanned from
the time of their recurrence through 2002 to assess patterns of
survival and health care costs (which were inﬂated to 2003
dollars). Patients who did not have recurrence were used as con-
trols. Techniques pioneered by Lin for the analysis of censored
cost data were used to estimate ten-year undiscounted costs of
recurrence by type. RESULTS: We identiﬁed 8725 patients in
SEER who were diagnosed with and treated for primary breast
cancer during 1991–1993, including 1485 who subsequently 
had a recurrence (local, 759; contralateral, 228; distant, 498).
Median survival was 124.0 months among controls, versus 
42.8 and 7.1 months among patients with local and distant
recurrence, respectively; 52.4% of patients with contralateral
recurrence remained alive after all data were censored at 93.5
months. Cumulative ten-year costs following local, contralateral,
and distant breast cancer recurrence exceeded those of controls
by $84,406, $29,609, and $222,106, respectively. CONCLU-
SION: The impact of breast cancer recurrence on patient sur-
vival and economic costs is substantial and varies considerably
by type.
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OBJECTIVES: Both bicalutamide and ﬂutamide are commonly
used in combined androgen blockade (CAB) for prostate cancer.
Although bicalutamide is more costly than ﬂutamide, it is impor-
tant that efﬁcacy and quality of life outcomes as well as com-
pliance, and side effects are also taken into consideration when
determining whether CAB with bicalutamide is a cost-effective
option as compared to CAB with ﬂutamide. Unfortunately, there
have been no well-designed cost-effectiveness analyses compar-
ing bicalutamide vs. ﬂutamide as part of CAB. The goal of this
study was to determine the cost-effectiveness of CAB with bica-
lutamide vs. CAB with ﬂutamide in men with stage D2 prostate
cancer. METHODS: A decision model was created to compare
treatment strategies. Survival and side effect information was
